Abstract
Parkinson Disease (PD) is a common neurodegenerative disorder of intricate etiology, caused by progressive loss of aminergic neurons and accumulation of Lewy bodies. The predominant role of genetics in the etiology of the disease has emerged since the identification of the first pathogenetic mutation in SNCA (alpha-synuclein) gene, back in 1997. Mendelian parkinsonisms, a minority among all PD forms, have been deeply investigated, with 19 loci identified. More recently, genome wide association studies have provided convincing evidence that variants in some of these genes, as well as in other genes, may confer an increased risk for late onset, sporadic PD. Moreover, the finding that heterozygous mutations in the GBA gene (mutated in Gaucher disease) are among the strongest genetic susceptibility factors for PD, has widened the scenario of PD genetic background to enclose a number of genes previously associated to distinct disorders, such as genes causative of spinocerebellar ataxias, mitochondrial disorders and fragile X syndrome. At present, the genetic basis of PD defines a continuum from purely mendelian forms (such as those caused by autosomal recessive genes) to multifactorial inheritance, resulting from the variable interplay of many distinct genetic variants and environmental factors.
Keywords: Genetics, monogenic, multifactorial, Parkinson disease, parkinsonism, risk factor.
Current Molecular Medicine
Title:Parkinson Disease Genetics: A "Continuum" from Mendelian to Multifactorial Inheritance
Volume: 14 Issue: 8
Author(s): S. Petrucci, F. Consoli and E.M. Valente
Affiliation:
Keywords: Genetics, monogenic, multifactorial, Parkinson disease, parkinsonism, risk factor.
Abstract: Parkinson Disease (PD) is a common neurodegenerative disorder of intricate etiology, caused by progressive loss of aminergic neurons and accumulation of Lewy bodies. The predominant role of genetics in the etiology of the disease has emerged since the identification of the first pathogenetic mutation in SNCA (alpha-synuclein) gene, back in 1997. Mendelian parkinsonisms, a minority among all PD forms, have been deeply investigated, with 19 loci identified. More recently, genome wide association studies have provided convincing evidence that variants in some of these genes, as well as in other genes, may confer an increased risk for late onset, sporadic PD. Moreover, the finding that heterozygous mutations in the GBA gene (mutated in Gaucher disease) are among the strongest genetic susceptibility factors for PD, has widened the scenario of PD genetic background to enclose a number of genes previously associated to distinct disorders, such as genes causative of spinocerebellar ataxias, mitochondrial disorders and fragile X syndrome. At present, the genetic basis of PD defines a continuum from purely mendelian forms (such as those caused by autosomal recessive genes) to multifactorial inheritance, resulting from the variable interplay of many distinct genetic variants and environmental factors.
Export Options
About this article
Cite this article as:
Petrucci S., Consoli F. and Valente E.M., Parkinson Disease Genetics: A "Continuum" from Mendelian to Multifactorial Inheritance, Current Molecular Medicine 2014; 14 (8) . https://dx.doi.org/10.2174/1566524014666141010155509
DOI https://dx.doi.org/10.2174/1566524014666141010155509 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
Call for Papers in Thematic Issues
Metabolic Reprogramming and Molecular Pharmacology: Innovations in Drug Discovery and Therapeutic Targeting
Metabolic reprogramming is a hallmark of numerous diseases, including cancer, metabolic disorders, and neurodegeneration. Understanding the intricate cell signaling pathways, transduction pathways, and omics-based data is important for the development of novel pharmacological interventions. This special issue of Current Molecular Medicine will be devoted to the current advances in drug ...read more
Molecular and Cellular Mechanisms in Vertigo / Vestibular Disorders
Vertigo and vestibular diseases are common among middle-aged and older adults, significantly increasing the risk of falls and leading to injuries and disabilities. Despite their prevalence, therapeutic advancements are hindered by a limited understanding of the underlying molecular and cellular mechanisms. This Special Issue is dedicated to bridging this gap ...read more
Related Journals

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Protein Aggregation and Defective RNA Metabolism as Mechanisms for Motor Neuron Damage
CNS & Neurological Disorders - Drug Targets Lipid Nanoparticles as Carriers for the Treatment of Neurodegeneration Associated with Alzheimer’s Disease and Glaucoma: Present and Future Challenges
Current Pharmaceutical Design Therapeutic, Molecular and Computational Aspects of Novel Monoamine Oxidase (MAO) Inhibitors
Combinatorial Chemistry & High Throughput Screening Subject Index to Volume 5
Current Genomics Histone Deacetylase Inhibitors: Therapeutic Agents and Research Tools for Deciphering Motor Neuron Diseases
Current Medicinal Chemistry Redox Active Iron at the Center of Oxidative Stress in Alzheimer Disease
Letters in Drug Design & Discovery Inhibitors of 11β-HSD1: A Potential Treatment for the Metabolic Syndrome
Current Topics in Medicinal Chemistry Assembly In Vitro of Tau Protein and its Implications in Alzheimers Disease
Current Alzheimer Research New Therapeutic Drugs from Bioactive Natural Molecules: The Role of Gut Microbiota Metabolism in Neurodegenerative Diseases
Current Drug Metabolism Lessons from Alzheimer's Disease (AD) Clinical Trials: Instead of “A-Drug”, AD-D prevention to Avert AD
Current Alzheimer Research Complement C4A and C4B Gene Copy Number Study in Alzheimer's Disease Patients
Current Alzheimer Research Regulation of Neurogenesis and Gliogenesis by Stress and Antidepressant Treatment
CNS & Neurological Disorders - Drug Targets Tetralone Scaffolds and Their Potential Therapeutic Applications
Letters in Drug Design & Discovery Ginsenoside Rg1 Attenuates Oligomeric Aβ1-42-Induced Mitochondrial Dysfunction
Current Alzheimer Research AMPA Receptor Potentiators: Application for Depression and Parkinsons Disease
Current Drug Targets Noscapine and its Analogs as Chemotherapeutic Agent: Current updates
Current Topics in Medicinal Chemistry Altered Glutamate Neurotransmission and Behaviour in Dementia: Evidence from Studies of Memantine
Current Molecular Pharmacology Neuroprotective Effects of Exercise Treatments After Injury: The Dual Role of Neurotrophic Factors
Current Neuropharmacology The Combination of rTMS and Pharmacotherapy on In Vitro Models: A Mini-Review
CNS & Neurological Disorders - Drug Targets Ribonucleases and ImmunoRNases as Anticancer Drugs
Current Pharmaceutical Design